Navigation Links
Aegera initiates Phase 1 clinical trial of AEG33773 - A small molecule in development for diabetic neuropathic pain
Date:3/18/2008

MONTREAL, March 18 /PRNewswire/ - Aegera Therapeutics announced today the initiation of a Phase 1, first-in-man, clinical trial for AEG33773, a novel, orally bioavailable small molecule in development for the treatment of painful diabetic neuropathy. The Phase I study will evaluate the safety, tolerability and pharmacokinetic profile of AEG33773 using a randomized, double blind, placebo controlled, single ascending dose design in healthy male volunteers.

Aegera completed a comprehensive pre-clinical development program on AEG33773, culminating in regulatory clearance from Health Canada and treatment of a first patient, in less than 12 months.

"We are extremely excited about the potential for AEG33773 to treat painful diabetic neuropathy and to expand to other pain and neuropathy indications, based on our extensive preclinical experience with this family of compounds in multiple models of pain and neuropathy," commented Dr. Jon Durkin, Vice-President Research and Preclinical Development at Aegera.

"This important milestone was achieved in record time, as the Aegera team has successfully filed regulatory applications for two potential blockbuster compounds, AEG33773 and AEG40826, in the last three months while initiating multiple Phase 2 trials for our lead program AEG35156. Aegera now has four unique programs in clinical development and is poised to deliver significant clinical data over the next 12-18 months" added Dr. Michael J. Berendt, Aegera's President and CEO.

About AEG33773

AEG33773 was developed as an orally bioavailable small molecule compound which provides acute pain relief in preclinical models of neuropathic and inflammatory pain. In addition, AEG33773's unique mechanism of action has demonstrated excellent in vivo activity in models of diabetic neuropathy with respect to its ability to not only prevent, but also to reverse established neuropathies.

About Aegera Therapeutics Inc.

Aegera Therapeutic
'/>"/>

SOURCE AEGERA THERAPEUTICS INC.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Human Genome Sciences and Aegera Therapeutics Announce Licensing and Collaboration Agreement on Novel Anti-Cancer Drugs
2. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
3. Dawson James Securities Initiates Research Coverage on CryoCor, Inc. (Nasdaq: CRYO) with a Strong Buy Rating and $6.00 Target Price
4. Spectrum Pharmaceuticals Initiates Second Registrational Phase 3 Clinical Trial for EOquin(R) in Patients With Non-Invasive Bladder Cancer
5. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
6. Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial
7. Cytochroma initiates Phase I/II clinical trial of CTAP101 Capsules for vitamin D insufficiency in chronic kidney disease
8. Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
9. GeneNews initiates patient sample accrual for validation studies of colon cancer blood test
10. Human Genome Sciences Initiates Second Randomized Phase 2 Trial of HGS-ETR1 in Combination With Chemotherapy
11. Conatus Pharmaceuticals Initiates a Phase 2 Clinical Trial for the Treatment of Hepatitis

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/9/2009)... The Appignani Bioethics...ation, held a panel discussion today at the Nation...chnologies in biomedical sciences and climate chan...Andrew Light, both of the Center for American Prog...olitical angles. ,, A video of the event will ...
(Date:11/9/2009)...9 /PRNewswire-Asia/ -- The pharma and biotech sect...e companies are facing significant,pressure to cha...costs, calls for,lower prices and a greater regula...nancial crisis have made the work of creating new ...es are being forced to globalize their R&D,ope...
(Date:11/9/2009)...r 9 Following the provision of cli...Administration (FDA), privately,owned UK company D...national.com ) has been informed that its innovati...rded an Orphan-Drug,designation for the treatment ... ALS, also known as Lou Gehrig,s disease, is the m...
(Date:11/6/2009).... 6 BioSpecifics Technol...company developing first-in-class collagenase-base...for the third quarter ended September 30, 2009. ,...f this year, the FDA,s Arthritis Advisory Committe...approval of XIAFLEX(TM) for the treatment of Dupuy...
Breaking Biology Technology:Jonathan Moreno and Andrew Light Speak About Biotechnology and Global Warming at the National Press Club 2Jonathan Moreno and Andrew Light Speak About Biotechnology and Global Warming at the National Press Club 3Pharma and Biotech Leaders to Converge in Shanghai 2Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 2Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 3Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 4Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 5Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 6
...ence,Corporation (Nasdaq: CSCX ), a global leader...bilitation, and informatics products, announced to...nancial results on Wednesday,April 30, 2008 after ...erence call with analysts and investors for 4:30 p...for the first quarter and current business,develop...
...cancer would find a noninvasive method to determin...ause low levels of oxygen in a tumor have been lin... to image the surrounding organs and tissues at th...umors in mice by Murali Krishna and colleagues, at...importance of this technical advance for furtherin...
...st-selling,biologics developed during the boom yea... hormone (hGH) and insulin, have lost patent,prote...y represent a market,of $40 billion. This opens up...atory hurdles can be overcome, according to a new ...orld Market for Biosimilars., Worldwide interest ...
Other Biology Technology:Cardiac Science Schedules First Quarter Earnings Release and Announces Conference Call 2Huge Potential in Biosimilars if Generic Providers Overcome Regulatory Hurdles 2
(Date:11/9/2009)...David Queller and Joan Strassmann argue in a new p...n components, from the genetic level on up, give a...ing is an animal, a plant, a bacteria or a colony...e an organism, such as individuality or even membe... achieve organismality. What is necessary, they ar...
(Date:11/9/2009)... / b3c newswire / - Today, TNO, a Dutch contrac...ican organization for contract research and consul...etter of intent with regard to TNOs dynamic in vi...tent proposes a collaboration in which Seventh Wav...n in North America. The TIM systems will be used t...
(Date:11/8/2009)... a gene through deletion of genetic material on ch...lities in learning and behavior, said a consortium...( www.bcm.edu ) in a report that appears online to...search goes about 95 percent of the way to pinning... to this gene," said Dr. Arthur L. Beaudet ( http:...
Breaking Biology News(10 mins):What is the meaning of 'one'? 2What is the meaning of 'one'? 3TNO and Seventh Wave sign letter of intent on joint preclinical pharmaceutical outsourcing services 2Developmental delay could stem from nicotinic receptor deletion 2Diagnostic tools and innovative therapies improve patient prognosis 53431 1Diagnostic tools and innovative therapies improve patient prognosis 53431 2Diagnostic tools and innovative therapies improve patient prognosis 53431 3Diagnostic tools and innovative therapies improve patient prognosis 53431 4Diagnostic tools and innovative therapies improve patient prognosis 53431 5Diagnostic tools and innovative therapies improve patient prognosis 53431 6Rock Climbing Injury Rate Soaring 53430 1Rock Climbing Injury Rate Soaring 53430 2Men Around the World Seek Cosmetic Surgery 53428 1Men Around the World Seek Cosmetic Surgery 53428 2
...sor of Clinical Tropical Medicine at the London Sc...d the first Hideyo Noguchi Africa Prize for resear...eir Majesties the Emperor and Empress of Japan at ...ideyo Noguchi Prize aims to award individuals with...research and health services, and seeks to encoura...
... Savage-Rumbaugh, Scientist With Special Standing ...eld of ape language and cognition studies, recentl...egree conferred in the 103-year history of her alm... , Savage-Rumbaugh, an internationally known prim...trated that through early rearing experiences, bon...
...local-source energy. Faster, more reliable technol...anguage. Medical care tailored to your DNA, or neu...ological diseases and injuries. , Five University...tures of energy, health, and technology as part of...they received this year from the National Science ...
Other Biology News:Professor Brian Greenwood awarded first Hideyo Noguchi Africa Award 2Ape language pioneer Savage-Rumbaugh receives honorary Ph.D. from alma mater 2Ape language pioneer Savage-Rumbaugh receives honorary Ph.D. from alma mater 3Ape language pioneer Savage-Rumbaugh receives honorary Ph.D. from alma mater 4Ape language pioneer Savage-Rumbaugh receives honorary Ph.D. from alma mater 5Pitt faculty receive awards to explore next-generation technologies 2Pitt faculty receive awards to explore next-generation technologies 3Pitt faculty receive awards to explore next-generation technologies 4
Luminex 100 IS System from Luminex Corporation
GIBCO Water Distilled Sterile from Invitrogen
GIBCO Water distilled from Invitrogen
Yeast Deletion Parental Strains S. cerevisiae Hansen BY4742 from Invitrogen
Biology Products: